Protara Therapeutics, Inc. (TARA)
NASDAQ: TARA · Real-Time Price · USD
3.220
-0.050 (-1.53%)
At close: May 13, 2025, 4:00 PM
3.260
+0.040 (1.24%)
Pre-market: May 14, 2025, 8:41 AM EDT

Protara Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2017 - 2019
Period Ending
Mar '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2017 - 2019
Selling, General & Admin
18.3217.4518.6220.7426.422.46
Upgrade
Research & Development
33.131.724.9916.8121.0911.98
Upgrade
Operating Expenses
51.4349.1543.6137.5547.4934.44
Upgrade
Operating Income
-51.43-49.15-43.61-37.55-47.49-34.44
Upgrade
Interest Expense
------0.03
Upgrade
Interest & Investment Income
5.144.173.191.110.240.5
Upgrade
Other Non Operating Income (Expenses)
0.870.39----
Upgrade
EBT Excluding Unusual Items
-45.42-44.6-40.42-36.44-47.25-33.98
Upgrade
Impairment of Goodwill
----29.52--
Upgrade
Pretax Income
-45.42-44.6-40.42-65.95-47.25-33.98
Upgrade
Net Income
-45.42-44.6-40.42-65.95-47.25-33.98
Upgrade
Net Income to Common
-45.42-44.6-40.42-65.95-47.25-33.98
Upgrade
Shares Outstanding (Basic)
28211111117
Upgrade
Shares Outstanding (Diluted)
28211111117
Upgrade
Shares Change (YoY)
145.71%81.73%0.64%0.24%55.28%180.66%
Upgrade
EPS (Basic)
-1.63-2.17-3.57-5.86-4.21-4.70
Upgrade
EPS (Diluted)
-1.63-2.17-3.57-5.86-4.21-4.70
Upgrade
Free Cash Flow
-40.25-35.87-37.6-26.58-35.1-24.29
Upgrade
Free Cash Flow Per Share
-1.44-1.74-3.32-2.36-3.13-3.36
Upgrade
EBITDA
-51.1-48.82-43.27-37.3-47.37-34.34
Upgrade
D&A For EBITDA
0.330.330.340.250.120.1
Upgrade
EBIT
-51.43-49.15-43.61-37.55-47.49-34.44
Upgrade
Updated May 8, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q